Our portfolio

Hipper Therapeutics

Hipper is a B2B company that focuses on improving recovery after hip fractures in elderly patients (80+) – with a value proposition around early discharge from care centres and improved rehabilitation outcome. The revalidation centres (the customer) is the entity that covers the cost.

Put simply after a patient has fallen they are worried about falling again (lack confidence). This reduces activity levels which impacts rehabilitation and can lead to a downward cycle. Hipper monitors activity and enables a therapist to use a data-driven approach for both physical and mental rehabilitation. Efficacy of the system has been validated via trials with the AMC (IP rights exchanged for equity).

Started within HvA, orginally operated as a VOF since late 2017 (MP and BK), turned into a BV in 2020 due to increasing commercial traction and to control liability.

Some ongoing collaboration/grant applications with AMC via Bianca Buurman.

Industry: Digital Health, Rehabilitation

Want to get in contact about Hipper Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Ross Gordon

Chemistry, Biotech & AI

Our portfolio

Check out similar ventures

Reducing plastic waste and lowering CO2 emissions.
Advancing molecular diagnostics for precision oncology and infectious diseases.
Transforming content into audio-based e-learning for on-the-go learning.
Optimizing sleep quality with science-backed technology.
Reducing plastic waste and lowering CO2 emissions.
Advancing molecular diagnostics for precision oncology and infectious diseases.
Transforming content into audio-based e-learning for on-the-go learning.
Optimizing sleep quality with science-backed technology.